JP2021534835A5 - - Google Patents

Info

Publication number
JP2021534835A5
JP2021534835A5 JP2021536663A JP2021536663A JP2021534835A5 JP 2021534835 A5 JP2021534835 A5 JP 2021534835A5 JP 2021536663 A JP2021536663 A JP 2021536663A JP 2021536663 A JP2021536663 A JP 2021536663A JP 2021534835 A5 JP2021534835 A5 JP 2021534835A5
Authority
JP
Japan
Prior art keywords
domain
target
binding domain
receptor
chimeric polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536663A
Other languages
English (en)
Japanese (ja)
Other versions
JP7474769B2 (ja
JP2021534835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049158 external-priority patent/WO2020047473A1/en
Publication of JP2021534835A publication Critical patent/JP2021534835A/ja
Publication of JP2021534835A5 publication Critical patent/JP2021534835A5/ja
Priority to JP2024065081A priority Critical patent/JP7745032B2/ja
Application granted granted Critical
Publication of JP7474769B2 publication Critical patent/JP7474769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536663A 2018-08-30 2019-08-30 一本鎖および多鎖キメラポリペプチドならびにその使用方法 Active JP7474769B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024065081A JP7745032B2 (ja) 2018-08-30 2024-04-15 一本鎖および多鎖キメラポリペプチドならびにその使用方法

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201862724969P 2018-08-30 2018-08-30
US201862725010P 2018-08-30 2018-08-30
US201862725043P 2018-08-30 2018-08-30
US201862725038P 2018-08-30 2018-08-30
US62/725,010 2018-08-30
US62/725,038 2018-08-30
US62/725,043 2018-08-30
US62/724,969 2018-08-30
US201862746832P 2018-10-17 2018-10-17
US62/746,832 2018-10-17
US201862749007P 2018-10-22 2018-10-22
US62/749,007 2018-10-22
US201862749506P 2018-10-23 2018-10-23
US62/749,506 2018-10-23
US201962816683P 2019-03-11 2019-03-11
US62/816,683 2019-03-11
US201962817241P 2019-03-12 2019-03-12
US201962817244P 2019-03-12 2019-03-12
US201962817230P 2019-03-12 2019-03-12
US62/817,241 2019-03-12
US62/817,244 2019-03-12
US62/817,230 2019-03-12
US201962881088P 2019-07-31 2019-07-31
US201962881039P 2019-07-31 2019-07-31
US62/881,088 2019-07-31
US62/881,039 2019-07-31
PCT/US2019/049158 WO2020047473A1 (en) 2018-08-30 2019-08-30 Single-chain and multi-chain chimeric polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065081A Division JP7745032B2 (ja) 2018-08-30 2024-04-15 一本鎖および多鎖キメラポリペプチドならびにその使用方法

Publications (3)

Publication Number Publication Date
JP2021534835A JP2021534835A (ja) 2021-12-16
JP2021534835A5 true JP2021534835A5 (enExample) 2022-08-26
JP7474769B2 JP7474769B2 (ja) 2024-04-25

Family

ID=67982166

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021536660A Active JP7449292B2 (ja) 2018-08-30 2019-08-30 加齢関連障害の治療法
JP2021536663A Active JP7474769B2 (ja) 2018-08-30 2019-08-30 一本鎖および多鎖キメラポリペプチドならびにその使用方法
JP2024031433A Active JP7773577B2 (ja) 2018-08-30 2024-03-01 加齢関連障害の治療法
JP2024065081A Active JP7745032B2 (ja) 2018-08-30 2024-04-15 一本鎖および多鎖キメラポリペプチドならびにその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021536660A Active JP7449292B2 (ja) 2018-08-30 2019-08-30 加齢関連障害の治療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024031433A Active JP7773577B2 (ja) 2018-08-30 2024-03-01 加齢関連障害の治療法
JP2024065081A Active JP7745032B2 (ja) 2018-08-30 2024-04-15 一本鎖および多鎖キメラポリペプチドならびにその使用方法

Country Status (8)

Country Link
US (4) US11672826B2 (enExample)
EP (3) EP4592314A3 (enExample)
JP (4) JP7449292B2 (enExample)
CN (4) CN120365435A (enExample)
AU (4) AU2019328567B2 (enExample)
CA (2) CA3109361A1 (enExample)
IL (2) IL280919B2 (enExample)
WO (2) WO2020047462A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス, インコーポレイテッド 免疫刺激性融合分子およびその使用
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
JP7713393B2 (ja) * 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
EP4157460A1 (en) * 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230117341A (ko) 2020-10-20 2023-08-08 큐라 테라퓨틱스, 인크. 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
TW202233661A (zh) * 2020-10-20 2022-09-01 美商克拉治療股份有限公司 多功能及多價介白素-TGF-β受體融合多肽
CN114569708B (zh) * 2020-12-02 2023-07-04 四川大学华西医院 Nkg2d car-免疫细胞在抗衰老中应用
CN117120075A (zh) * 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
EP4079846A1 (en) * 2021-04-23 2022-10-26 SVAR Life Science AB Novel luciferases with improved properties
WO2022260849A1 (en) * 2021-06-09 2022-12-15 Nant Holdings Ip, Llc Methods and systems for producing a protein of interest in a plant
CN115477705B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗原ターゲティング、抗cd16aおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
EP4429773A1 (en) * 2021-11-08 2024-09-18 Albert Einstein College of Medicine Methods, compositions, and kits for modifying immune cell activity via kir2dl5
WO2023090901A1 (ko) * 2021-11-18 2023-05-25 의료법인 성광의료재단 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
CN114262382B (zh) * 2021-12-20 2023-09-19 上海恩凯细胞技术有限公司 双特异性抗体及其应用
WO2023133357A2 (en) * 2022-01-10 2023-07-13 Expression Therapeutics, Llc Engineered t cells
US20240075141A1 (en) 2022-03-18 2024-03-07 WUGEN, Inc. Chimeric receptor constructs for nk cells
US20230330228A1 (en) 2022-03-22 2023-10-19 WUGEN, Inc. Hybrid promoters, vectors containing same and methods of use
JP2025512431A (ja) * 2022-04-11 2025-04-17 デューク ユニバーシティ 組換えtim-4タンパク質、キメラ抗原受容体(car)t細胞送達システム及びそれを作製し、使用する方法
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
JP2025539364A (ja) * 2022-11-22 2025-12-05 エクスプレッション セラピューティクス, エルエルシー 遺伝子操作t細胞
CN116271008A (zh) * 2022-12-30 2023-06-23 广东天普生化医药股份有限公司 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用
EP4648854A1 (en) * 2023-01-10 2025-11-19 Expression Therapeutics, LLC Engineered t cells
CN121889492A (zh) * 2023-07-21 2026-04-17 盖亚生物制药有限公司 细胞群的制备方法
WO2026043906A1 (en) * 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20260049118A1 (en) * 2024-08-19 2026-02-19 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
DE69519929T2 (de) 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
AU2270101A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003239197A1 (en) 2002-06-07 2003-12-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Novel stable anti-cd22 antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1599502A1 (en) 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
CA2518854A1 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
US7618632B2 (en) * 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
JP2005124568A (ja) 2003-10-01 2005-05-19 Junichi Masuyama 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
DK1863905T3 (en) 2005-03-17 2016-04-04 Ucl Business Plc PROCEDURE FOR ACTIVATING NATURAL KILLER CELLS USING VITRO TUMOR CELL PREPARATIONS
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス, インコーポレイテッド ヒト化抗cd70結合剤およびその使用
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20100310504A1 (en) * 2007-09-26 2010-12-09 Lowe Scott W Methods for treating fibrosis by modulating cellular senescence
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130036192A (ko) 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-cd200 항체들을 이용한 치료 및 진단 방법
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
CN102153653B (zh) 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
WO2012147713A1 (ja) 2011-04-25 2012-11-01 第一三共株式会社 抗b7-h3抗体
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
WO2012170470A1 (en) 2011-06-06 2012-12-13 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原(Trop-2)之專一性抗體類及彼等之用途
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
EP2890713A1 (en) 2012-08-28 2015-07-08 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトcd26モノクローナル抗体又はその抗原結合性断片
CN103709251B (zh) 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
HUE045065T2 (hu) * 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
DK3186283T3 (da) 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
CN108064245A (zh) 2015-04-17 2018-05-22 埃尔萨里斯生物技术公司 抗Tyro3抗体及其用途
KR101778439B1 (ko) 2015-04-27 2017-09-14 울산대학교 산학협력단 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
JP6931228B2 (ja) 2015-09-11 2021-09-01 ワイズ・エー・シー株式会社 抗cd26抗体と他の抗癌剤とを組み合わせた癌治療用組成物
PE20181046A1 (es) 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso
EP3373970A4 (en) 2015-11-13 2019-07-10 Dana Farber Cancer Institute, Inc. NKG2D IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
WO2017189526A1 (en) 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
DK3523416T3 (da) 2016-10-05 2025-03-03 Univ Central Florida Res Found Inc Fremgangsmåder og sammensætninger relateret til nk-celle- og anti-pdl1-kræftbehandlinger
EP4613776A3 (en) * 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
US20210230221A1 (en) 2017-01-03 2021-07-29 Bioatla, Llc Protein therapeutics for treatment of senescent cells
AU2018226526B2 (en) 2017-02-28 2025-03-13 Affimed Gmbh Combination of an anti-CD16A antibody with a cytokine
KR102867975B1 (ko) 2017-03-06 2025-10-14 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
KR20190126182A (ko) 2017-03-27 2019-11-08 난트셀, 인크. aNK 및 IL-12 조성물 및 방법 (ANK AND IL-12 COMPOSITIONS AND METHODS)
JP2020533971A (ja) 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Il−15をベースとするil−7及びil−21への融合物
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders

Similar Documents

Publication Publication Date Title
JP2021534835A5 (enExample)
JP2021534828A5 (enExample)
JP2021534829A5 (enExample)
US20230295567A1 (en) Methods for culturing cells and kits and apparatus for same
TWI809130B (zh) 嵌合跨膜蛋白及其用途
AU2017301880C1 (en) Immunomodulatory polypeptides and related compositions and methods
IL295878A (en) Methods for producing cells expressing a chimeric antigen receptor
CN111417652A (zh) 嵌合多肽及其用途
KR20230164219A (ko) 올리고머 입자 시약 및 이의 사용 방법
JP7433348B2 (ja) キメラポリペプチド及びそれらの細胞膜における局在を変更する方法
JP2022541742A5 (enExample)
WO2019126358A1 (en) Single- and multi-chain chimeric antigen receptors
AU2022234333B2 (en) Improving immune cell function
JP2023515747A5 (enExample)
CN111848818A (zh) 一种增强型免疫细胞及其应用
CN121969385A (zh) 含有il-2变体以增强car t细胞的功能性的car-衔接子
JP2025533858A (ja) 多特異性タンパク質および関連する方法
TW202600602A (zh) 4-1bb配體細胞外域的突變蛋白、包含其的融合蛋白及其用途
CN120591212A (zh) 一种超高能量免疫细胞及其制备方法
TW202544028A (zh) 新穎il—21突變、包含彼之融合蛋白,以及其用途
WO2026015853A1 (en) Enhancing activity and persistence of car-nk cells for the treatment of cancer and autoimmune diseases
WO2024011335A1 (zh) 经修饰的免疫细胞
HK40046928A (en) Chimeric transmembrane proteins and uses thereof
HK40013683A (en) Chimeric polypeptides and methods of altering their localisation in the cell membrane